This study will test an investigational drug called BAN2401 for the treatment of individuals with preclinical Alzheimer's Disease. Participation may last up to 4 years.
This study is composed of two research trials aimed at preventing Alzheimer's Disease (AD) dementia. One is called AHEAD-3 and the other is called AHEAD-45. You may qualify to join one of the AHEAD Study prevention trials because you're aged 55-80 years and have normal memory and thinking abilities.
General Inclusion Criteria:
Only individuals who have intermediate or elevated levels of amyloid in their brain will be able to participate in these studies. The screening process for the AHEAD Study will use a Positron Emission Tomography (PET) scan to measure the level of amyloid in your brain.
Must have a study partner that is willing to participate as a source of information and who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, or caregiver).